Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors. Rilotumumab was in development by Amgen, Inc...
3 KB (127 words) - 15:28, 19 May 2023
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
121 KB (13,791 words) - 00:45, 15 May 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
68 KB (5,993 words) - 03:20, 20 May 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
150 KB (15,741 words) - 22:02, 27 May 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
31 KB (3,413 words) - 22:16, 21 March 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
17 KB (1,489 words) - 05:47, 7 April 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
9 KB (524 words) - 02:56, 27 April 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
8 KB (418 words) - 13:31, 24 May 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
14 KB (1,671 words) - 12:47, 23 April 2024
Volitinib Antibodies: Emibetuzumab Ficlatuzumab Flanvotumab Onartuzumab Rilotumumab Telisotuzumab Telisotuzumab vedotin IGF LNGF (p75NTR) Agonists: BDNF...
12 KB (1,049 words) - 10:54, 12 January 2024